Nektar Therapeutics has said phase 2b results show it was right to keep faith with rezpegaldesleukin as a therapy for atopic dermatitis (AD), also known as eczema. Data from the REZOLVE-AD study of ...

Nektar Therapeutics is advancing Rezpeg, a Treg-expanding biologic, in atopic dermatitis and alopecia areata, or AA, after regaining rights from Eli Lilly. Rezpeg demonstrated modest efficacy and good ...

Nektar Therapeutics (NASDAQ: NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what ...

The drug and biotech sector witnessed a see-saw performance in 2025. After a weak show for most of the year, the sector picked up in the past couple of months. This can be attributed to improved ...

SHENZHEN, China, Dec. 19, 2025 /PRNewswire/ -- One week after its Kickstarter debut, Anycubic's Photon P1 has attracted more than 1,200 backers and raised nearly US$880,000, signaling strong early ...

British cardiologist shares two-word trick to lower blood pressure fast Akshaye Khanna asked Dhurandhar co-actor to slap him so hard, he falls: 'I was hesitant while beating up the senior actor' ...

With strong 1-year returns and upside potential, Nektar Therapeutics (NASDAQ: NKTR ) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026 Nektar Therapeutics ...

With strong 1-year returns and upside potential, Nektar Therapeutics (NASDAQ:NKTR) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also ...

Patriots CB Christian Gonzalez cleared to play on Sunday, Texans star Nico Collins ruled out ...